US equities
|
MU
$931.24
▲+1.87%
NVDA
$217.23
▼-1.84%
SNDK
$1,394.83
▼-0.61%
AMD
$562.23
▼-1.50%
SPCX
$148.62
▼-2.33%
INTC
$95.37
▼-2.80%
AAPL
$342.00
▼-0.28%
MSFT
$539.44
▲+1.08%
MU
$931.24
▲+1.87%
NVDA
$217.23
▼-1.84%
SNDK
$1,394.83
▼-0.61%
AMD
$562.23
▼-1.50%
SPCX
$148.62
▼-2.33%
INTC
$95.37
▼-2.80%
AAPL
$342.00
▼-0.28%
MSFT
$539.44
▲+1.08%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Ocular Therapeutix, Inc. - Common Stock
(NQ:
OCUL
)
7.380
+0.180 (+2.50%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ocular Therapeutix, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
1 Russell 2000 Stock with Solid Fundamentals and 2 We Avoid
October 15, 2026
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...
Via
StockStory
Topics
Energy
Intellectual Property
3 Healthcare Stocks We Find Risky
October 13, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...
Via
StockStory
3 Unprofitable Stocks Walking a Fine Line
October 12, 2026
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv...
Via
StockStory
1 Cash-Burning Stock for Long-Term Investors and 2 Facing Headwinds
October 09, 2026
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them...
Via
StockStory
Topics
Artificial Intelligence
Ocular Therapeutix Inc (NASDAQ:OCUL) Misses on Revenue and EPS in Q1 2026, Stock Dips
↗
May 05, 2026
Via
Chartmill
3 Stocks Under $10 That Fall Short
October 05, 2026
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying busi...
Via
StockStory
3 Reasons to Avoid OCUL and 1 Stock to Buy Instead
October 01, 2026
Over the last six months, Ocular Therapeutix’s shares have sunk to $7.74, producing a disappointing 7.1% loss - a stark contrast to the S&P 500’s 16.6% gain....
Via
StockStory
Topics
Stocks
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
September 28, 2026
Via
Chartmill
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know
September 23, 2026
What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid S...
Via
StockStory
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
↗
September 22, 2026
Ocular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a U.S. marketing application for AXPAXLI in the fourth quarter of this year, following what Chief Executive Officer Pravin Dugel...
Via
MarketBeat
1 Cash-Heavy Stock on Our Buy List and 2 Facing Challenges
September 01, 2026
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c...
Via
StockStory
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
August 20, 2026
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Oc...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Ocular Therapeutix (NASDAQ:OCUL) Beats Expectations in Strong Q2 CY2026
August 03, 2026
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) reported Q2 CY2026 results beating Wall Street’s revenue expectations, but sales wer...
Via
StockStory
3 Healthcare Stocks with Questionable Fundamentals
August 03, 2026
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...
Via
StockStory
3 Russell 2000 Stocks That Concern Us
July 31, 2026
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...
Via
StockStory
Pharmaceuticals Stocks Q1 In Review: Ocular Therapeutix (NASDAQ:OCUL) Vs Peers
July 26, 2026
Let’s dig into the relative performance of Ocular Therapeutix (NASDAQ:OCUL) and its peers as we unravel the now-completed Q1 pharmaceuticals earnings season....
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
↗
July 22, 2026
Ocular Therapeutix (NASDAQ:OCUL) said it remains on track to submit a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter, after what Executive Chairman,...
Via
MarketBeat
3 Cash-Burning Stocks with Open Questions
July 21, 2026
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sh...
Via
StockStory
Topics
Artificial Intelligence
3 Small-Cap Stocks with Open Questions
July 08, 2026
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and...
Via
StockStory
Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings?
June 24, 2026
Over the past six months, Ocular Therapeutix’s shares (currently trading at $10.37) have posted a disappointing 18.5% loss, well below the S&P 500’s 7.8% gai...
Via
StockStory
Topics
Stocks
Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos
June 18, 2026
Check out the companies making headlines yesterday: Nubank (NYSE:NU): Digital banking platform Nubank (NYSE:NU) rose by 3.2% on Wednesday after the company r...
Via
StockStory
Topics
Economy
Why Ocular Therapeutix (OCUL) Stock Is Up Today
June 17, 2026
What Happened? Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) jumped 7.2% in the afternoon session after the company anno...
Via
StockStory
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
↗
June 15, 2026
Two biotech innovators, two very different risk profiles: one with commercial products and another betting on next-gen gene editing breakthroughs.
Via
The Motley Fool
3 of Wall Street’s Favorite Stocks That Concern Us
June 10, 2026
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Via
StockStory
1 Russell 2000 Stock to Research Further and 2 Facing Headwinds
May 28, 2026
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However,...
Via
StockStory
Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1
↗
May 26, 2026
Ocular Therapeutix delivers FDA-approved eye therapies and devices, supported by a pipeline targeting multiple ocular diseases.
Via
The Motley Fool
Topics
Regulatory Compliance
Stocks
What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors
↗
May 19, 2026
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
Why Ocular Therapeutix (OCUL) Stock Is Nosediving
May 05, 2026
What Happened? Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) fell 5.8% in the afternoon session after the company report...
Via
StockStory
Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings
May 05, 2026
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) missed Wall Street’s revenue expectations in Q1 CY2026, with sales flat year on year...
Via
StockStory
Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect
May 03, 2026
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) will be announcing earnings results this Tuesday before the bell. Here’s what to loo...
Via
StockStory
< Previous
1
2
3
4
5
6
7
8
9
Next >
